Trial Status: Open
Ethos Discovery de novo Study
Sepsis is a common reason for emergency presentation in small animal practice. The successful treatment of sepsis is significantly corelated to the timeliness of its diagnosis and treatment, which can often prove challenging. There is a growing need to identify biochemical markers that can more promptly confirm the presence of sepsis and to monitor its response to treatment.
Human studies have shown that increased procalcitonin (PCT) concentrations strongly correlate with mortality in septic patients. A recent veterinary study demonstrated that, compared to healthy dogs, PCT levels were significantly greater in cases of sepsis. The results of this work highlight PCT as a promising biomarker for identifying sepsis and monitoring its response to treatment.
The goal of this study is to evaluate changes in procalcitonin levels over time in canine patients surgically treated for sepsis. Additional blood sample collection will also be performed to investigate for possible novel biomarkers for sepsis using next generation sequencing for the future development of a point of care molecular test.